Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells

BACKGROUND/AIMS: Silibinin, the main component of silymarin, is used as a hepatoprotectant and exhibits anticancer effects against various cancer cells. This study evaluated the effects of a combination of silibinin with either gefitinib or sorafenib on hepatocellular carcinoma (HCC) cells. METHODS:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Mol Hepatol
Main Authors: Gu, Ha Ra, Park, Su Cheol, Choi, Su Jin, Lee, Jae Cheol, Kim, You Cheoul, Han, Chul Ju, Kim, Jin, Yang, Ki Young, Kim, Yeon Joo, Noh, Geum Youb, No, So Hyeon, Jeong, Jae-Hoon
Formato: Artigo
Idioma:Inglês
Publicado em: The Korean Association for the Study of the Liver 2015
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4379197/
https://ncbi.nlm.nih.gov/pubmed/25834802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2015.21.1.49
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados